Genocea to Present at Cantor Fitzgerald Healthcare Conference

CAMBRIDGE, Mass., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. GNCA, a biopharmaceutical company developing novel vaccines and immunotherapies targeting T cell antigens,  today announced that Chip Clark, president and chief executive officer, will present a company overview at the Cantor Fitzgerald Healthcare Conference on Wednesday, September 27, 2017 at 10:20 a.m. ET in New York City.

A live webcast of the presentations can be accessed by visiting the "Events and Presentations" tab of the investor relations section of the Genocea website at http://ir.genocea.com. A replay of the webcasts will be archived for 30 days following the presentation.

About Genocea Biosciences, Inc.
Genocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. While traditional immunotherapy discovery methods have largely used predictive methods to propose T cell targets, or antigens, Genocea has successfully developed ATLAS™, its proprietary technology platform, to identify clinically relevant antigens of T cells based on actual human immune responses. Genocea used ATLAS to identify the antigens in its lead clinical candidate, GEN-003, an investigational immunotherapy to treat genital herpes, and is currently using ATLAS in immuno-oncology applications to develop neoantigen cancer vaccines (with an IND filing expected by the end of 2017), general cancer vaccines and a vaccine targeting cancers caused by Epstein-Barr Virus. For more information, please visit www.genocea.com.

For media:
Jennifer LaVin
O: 617-715-6687
jennifer.lavin@genocea.com

For investors:
Jonathan Poole
O: 617-876-8191
jonathan.poole@genocea.com